204 related articles for article (PubMed ID: 37407805)
21. A hypoxia-related signature for clinically predicting diagnosis, prognosis and immune microenvironment of hepatocellular carcinoma patients.
Zhang B; Tang B; Gao J; Li J; Kong L; Qin L
J Transl Med; 2020 Sep; 18(1):342. PubMed ID: 32887635
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive analysis of prognostic value, relationship to cell cycle, immune infiltration and m6A modification of ZSCAN20 in hepatocellular carcinoma.
Jiayu F; Jiang Y; Zhou X; Zhou M; Pan J; Ke Y; Zhen J; Huang D; Jiang W
Aging (Albany NY); 2022 Dec; 14(23):9550-9578. PubMed ID: 36462500
[TBL] [Abstract][Full Text] [Related]
23. A prognostic risk model, tumor immune environment modulation, and drug prediction of ferroptosis and amino acid metabolism-related genes in hepatocellular carcinoma.
Ji L; Zhang Q; Cao Y; Liu L
Hum Cell; 2023 May; 36(3):1173-1189. PubMed ID: 36892792
[TBL] [Abstract][Full Text] [Related]
24. Identification of a Liver Progenitor Cell-Related Genes Signature Predicting Overall Survival for Hepatocellular Carcinoma.
Li X; Lin J; Pan Y; Cui P; Xia J
Technol Cancer Res Treat; 2021; 20():15330338211041425. PubMed ID: 34866477
[No Abstract] [Full Text] [Related]
25. Immune infiltration-associated serum amyloid A1 predicts favorable prognosis for hepatocellular carcinoma.
Zhang W; Kong HF; Gao XD; Dong Z; Lu Y; Huang JG; Li H; Yang YP
World J Gastroenterol; 2020 Sep; 26(35):5287-5301. PubMed ID: 32994688
[TBL] [Abstract][Full Text] [Related]
26. Development and Validation of a Novel Ferroptosis-Related Gene Signature for Prognosis and Immunotherapy in Hepatocellular Carcinoma.
Zhang B; Zhao J; Liu B; Shang Y; Chen F; Zhang S; He J; Fan Y; Tan K
Front Mol Biosci; 2022; 9():940575. PubMed ID: 35847985
[TBL] [Abstract][Full Text] [Related]
27. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
28. Tumor-adjacent tissue co-expression profile analysis reveals pro-oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma.
Grinchuk OV; Yenamandra SP; Iyer R; Singh M; Lee HK; Lim KH; Chow PK; Kuznetsov VA
Mol Oncol; 2018 Jan; 12(1):89-113. PubMed ID: 29117471
[TBL] [Abstract][Full Text] [Related]
29. Classification of the mitochondrial ribosomal protein-associated molecular subtypes and identified a serological diagnostic biomarker in hepatocellular carcinoma.
Xie C; Hu J; Hu Q; Jiang L; Chen W
Front Surg; 2022; 9():1062659. PubMed ID: 36684217
[TBL] [Abstract][Full Text] [Related]
30. A Novel Ferroptosis-Related Signature for Prediction of Prognosis, Immune Profiles and Drug Sensitivity in Hepatocellular Carcinoma Patients.
Zhao C; Zhang Z; Tao J
Curr Oncol; 2022 Sep; 29(10):6992-7011. PubMed ID: 36290827
[TBL] [Abstract][Full Text] [Related]
31. Identify an innovative ferroptosis-related gene in hepatocellular carcinoma.
Hu G; Huang X; Zhang B; Gao P; Wu W; Wang J
J Clin Lab Anal; 2022 Sep; 36(9):e24632. PubMed ID: 35908779
[TBL] [Abstract][Full Text] [Related]
32. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
33. [Screening core genes and cyclin B2 as a potential diagnosis, treatment and prognostic biomarker of hepatocellular carcinoma based on bioinformatics analysis].
Yang SY; Ren H; Li CF; Tang H
Zhonghua Gan Zang Bing Za Zhi; 2020 Sep; 28(9):773-783. PubMed ID: 33053978
[No Abstract] [Full Text] [Related]
34. Ferroptosis and cuproptosis prognostic signature for prediction of prognosis, immunotherapy and drug sensitivity in hepatocellular carcinoma: development and validation based on TCGA and ICGC databases.
Ma Q; Hui Y; Huang BR; Yang BF; Li JX; Fan TT; Gao XC; Ma DY; Chen WF; Pei ZX
Transl Cancer Res; 2023 Jan; 12(1):46-64. PubMed ID: 36760376
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of long non-coding RNA
Liao X; Chen J; Luo D; Luo B; Huang W; Xie W
Pathol Oncol Res; 2022; 28():1610808. PubMed ID: 36685103
[No Abstract] [Full Text] [Related]
36. Comprehensive analyses of competing endogenous RNA networks reveal potential biomarkers for predicting hepatocellular carcinoma recurrence.
Yan P; Huang Z; Mou T; Luo Y; Liu Y; Zhou B; Cao Z; Wu Z
BMC Cancer; 2021 Apr; 21(1):436. PubMed ID: 33879119
[TBL] [Abstract][Full Text] [Related]
37. Bioinformatics Analysis of Candidate Genes and Pathways Related to Hepatocellular Carcinoma in China: A Study Based on Public Databases.
Zhang P; Feng J; Wu X; Chu W; Zhang Y; Li P
Pathol Oncol Res; 2021; 27():588532. PubMed ID: 34257537
[No Abstract] [Full Text] [Related]
38. High MRPS23 expression contributes to hepatocellular carcinoma proliferation and indicates poor survival outcomes.
Pu M; Wang J; Huang Q; Zhao G; Xia C; Shang R; Zhang Z; Bian Z; Yang X; Tao K
Tumour Biol; 2017 Jul; 39(7):1010428317709127. PubMed ID: 28714366
[TBL] [Abstract][Full Text] [Related]
39. Immune system‑associated genes increase malignant progression and can be used to predict clinical outcome in patients with hepatocellular carcinoma.
Huang R; Chen Z; Li W; Fan C; Liu J
Int J Oncol; 2020 May; 56(5):1199-1211. PubMed ID: 32319580
[TBL] [Abstract][Full Text] [Related]
40. Development and validation of four ferroptosis-related gene signatures and their correlations with immune implication in hepatocellular carcinoma.
Zhang Y; Ren H; Zhang C; Li H; Guo Q; Xu H; Cui L
Front Immunol; 2022; 13():1028054. PubMed ID: 36304446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
